Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis-Reference-Cited by-同舟云学术

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis

Published:2022-04-01 Issue:4 Volume:158 Page:404
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Simpson Eric L.¹,Papp Kim A.²,Blauvelt Andrew³,Chu Chia-Yu⁴,Hong H. Chih-ho⁵⁶⁷,Katoh Norito⁸,Calimlim Brian M.⁹,Thyssen Jacob P.¹⁰,Chiou Albert S.¹¹,Bissonnette Robert¹²,Stein Gold Linda F.¹³,Wegzyn Colleen⁹,Hu Xiaofei⁹,Liu Meng⁹,Liu John⁹,Tenorio Allan R.⁹,Chu Alvina D.⁹,Guttman-Yassky Emma¹⁴

Affiliation:

1. Department of Dermatology, Oregon Health & Science University, Portland

2. Probity Medical Research and K Papp Clinical Research, Waterloo, Ontario, Canada

3. Oregon Medical Research Center, Portland

4. Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

5. Dr Chih-ho Hong Medical, Inc, Surrey, British Columbia, Canada

6. Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada

7. Probity Medical Research, Surrey, British Columbia, Canada

8. Department of Dermatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

9. AbbVie Inc, North Chicago, Illinois

10. Bispebjerg University Hospital, University of Copenhagen, Copenhagen, Denmark

11. Department of Dermatology, Stanford University School of Medicine, Stanford, California

12. Innovaderm Research, Montreal, Quebec, Canada

13. Dermatology Clinical Research, Henry Ford Health System, West Bloomfield, Michigan

14. Department of Dermatology and the Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, New York

Publisher

American Medical Association (AMA)

Subject

Dermatology

Link

https://jamanetwork.com/journals/jamadermatology/articlepdf/2789438/jamadermatology_simpson_2022_oi_220003_1652816934.04797.pdf

Reference16 articles.

1. Systemic treatment of adult atopic dermatitis: a review.;Megna;Dermatol Ther (Heidelb),2017

2. Atopic dermatitis epidemiology and unmet need in the United Kingdom.;Cork;J Dermatolog Treat,2020

3. Understanding the immune landscape in atopic dermatitis: the era of biologics and emerging therapeutic approaches.;Moyle;Exp Dermatol,2019

4. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.;Simpson;N Engl J Med,2016

5. Pharmacokinetics of upadacitinib in healthy subjects and subjects with rheumatoid arthritis, Crohn’s disease, ulcerative colitis, or atopic dermatitis: population analyses of phase 1 and 2 clinical trials.;Nader;J Clin Pharmacol,2020

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Budget impact and cost per responder analysis of upadacitinib for the treatment of moderate to severe atopic dermatitis from the perspective of the social security and the private sector in Argentina;Expert Review of Pharmacoeconomics & Outcomes Research;2024-08-30

2. Consensus Recommendations for the Management of Atopic Dermatitis in the United Arab Emirates;Dermatology and Therapy;2024-08-22

3. Practical Recommendations on Laboratory Monitoring in Patients with Atopic Dermatitis on Oral JAK Inhibitors;Dermatology and Therapy;2024-08-08

4. 706 - Real-world patient experience of upadacitinib-treated adults with atopic dermatitis: results from the SCALE-UP study;British Journal of Dermatology;2024-08

5. 696 - Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies;British Journal of Dermatology;2024-08